'No One Has Said, "Ah, We've Got It All Figured Out"'
Surgeons perform almost 800,000 total-knee replacements, and more than a half-million hip replacements, in the United States each year.
And while those procedures are typically life- and mobility-enhancing, the initial post-surgical pain can be very unpleasant for some patients. Opioids remain among the most popular prescription medication to combat orthopedic post-surgical pain, but two UConn Health faculty members think they've found a better solution.
Researchers Lakshmi Nair, Ph.D. and Yusuf Khan, Ph.D., both associate professors in the Department of Orthopedic Surgery, believe they are on the cusp of a breakthrough pain-reduction treatment that is both highly effective and safe. Nair has been working to significantly extend the duration of local anesthetics, enabling patients to be pain-free, mobile, and benefit from medications that have been safely used for decades. The pain medication would be delivered by injection.
Their pharmaceutical company, Soleia Biosciences, has been identified as one of five extremely promising UConn-affiliated startups. They will be pitching in the Wolff New Venture Competition on Oct. 1 in Downtown Hartford.
Opioids Are the 'Most Feared' Treatment
"Opioids are among the most popular prescriptions, and most feared,'' Khan says. "We've spoken with doctors, patients, and pharmacists during our customer discovery research, and they universally agree there needs to be a better strategy. No one has said, 'Ah, we've got it all figured out!'''
Nair, who has been working on this pain-relief challenge for a decade, says the human responses to pain are complicated and complex.
"That may be why there is no great opioid alternative developed so far,'' she says. "We're entering the market with a niche solution. To provide alternative therapies for surgeons to recommend and offer that extended pain relief to patients is truly exciting.''
Khan says although opioids work well, they present considerable concern about addiction. Patients often speak with their family or their medical team and refuse to take opioids. They also present side effects in some patients, including stomach upset, sleeplessness and brain fog.
Soleia Bioscience Contending in Wolff Competition
Nair and Khan are excited to be competing in the Wolff New Venture Competition, which is the School of Business' pinnacle entrepreneurship challenge. The event, which is open to the public, will award more than $70,000 in prize money to participants, with the first-place finisher receiving a $30,000 check.
If they win the Wolff prize, Nair and Khan will hire FDA consultants to begin their formal application process, and will work to refine their scientific dosage studies followed by clinical trials.
New this year, a startup showcase is being added alongside the pitch competition. Thirty UConn startups will be exhibiting their technologies, products, and services. Among them are: Lambda Vision, a company developing the first protein-based artificial retina to restore vision for patients who are blind or have lost sight due to macular degeneration and other diseases, and Kona Brand, a clothing company that makes fun winter flannels with summer designs. Attendees will be able to purchase items from the startups that sell consumer products. The startup showcase companies will vie for $45,000 in in-kind prizes will be awarded.
Pre-Clinical Studies Are Already Underway
Nair has been working on developing pain management approaches for about a decade and she has completed many successful pre-clinical studies on animals. Earlier this year Hair and Khan participated in a National Science Foundation I-Corps program through UConn.
"Many scientists form the company first, and then complete the pre-clinical studies, so I think we're farther along in the process than we initially thought,'' Khan says. Although they are initially focused on orthopedic post-surgical care, they believe their formula will have multiple applications in the future.
The Connecticut Center for Entrepreneurship & Innovation extended an invitation to the Soleia Bioscience team to participate in its eight-week Summer Fellowship Accelerator, where the founders took business classes for entrepreneurs and met mentors who are eager to help them take the next-steps to grow their company. The experience was incredible, Khan says.
"We had to learn how to build from the ground up,'' Khan says. "We're researchers. We write articles and conduct experiments. CCEI gave us the map and showed us where to begin to establish ourselves as a business. The Center is rich with business advisers, mentors, and contacts.
"The best part is that just because the program is over, they're still there for us. We can pick up the phone at any time and they're willing to help,'' he says. "We got exactly what we hoped for from the program-and more.''
"After two months everything about our business trajectory went from fuzzy to clear,'' Nair says. "We know what we need to know, who to contact, and where to get help!''
The Wolff New Venture Competition will be held on Oct. 1 from 5:30 to 8:30 p.m. at the YG Club at Dunkin Park in Hartford. The event is free to attend, and all are welcome. Please pre-register at Wolff New Venture Competition.
The Competition is supported thanks to the generosity of the Wolff Family Fund for Strategic Entrepreneurship, as well as Revyrie, wiggin(x), Digital Surgeons, Santander, Sardilli Produce and Dairy, Prime Materials Recovery Inc., Webster Bank, Fiondella, Milone and LaSaracina CPAs, Baystate Financial, Mark and Jamie Summers, and Event Resources.
